{
  "id": 19556310,
  "title": "Oruka Therapeutics at Stifel 2026 Healthcare Conference 2026: annual dosing push",
  "url": "https://urgent.news/2026/11/11/oruka-therapeutics-at-stifel-2026-healthcare-conference-2026-annual",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-11T21:43:18.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/oruka-therapeutics-at-stifel-2026-healthcare-conference-2026-annual-dosing-push-93CH-5019905"
  },
  "original_language": "en",
  "account": "On November 11, 2026, Oruka Therapeutics (ORKA) unveiled ambitious plans for treating psoriatic disease during the Stifel 2026 Healthcare Conference. CEO Lawrence Klein emphasized the company's goal of achieving high efficacy with infrequent dosing. The primary focus was on ORKA-001, an IL-23p19 antibody, which showed promising week 16 response rates in two Phase II studies, exceeding current IL-23 leaders. ORKA-001 aims for annual dosing, with a December 2024 readout testing the feasibility of this approach. The company also discussed ORKA-002 and ORKA-004, which could target psoriatic arthritis and hidradenitis suppurativa. ORKA-001 boasts a strong cash position of $1.2 billion as of Q3 2024, sufficient to fund the BLA path and further studies.",
  "summary": null,
  "key_points": [
    "CEO Lawrence Klein highlights ORKA-001's high efficacy with infrequent dosing in Phase II studies.",
    "ORKA-001 aims for annual dosing, with December 2024 readout testing feasibility."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}